Endocrinology, Diabetes & Metabolism Case Reports (Nov 2019)

Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma

  • Alessandro Rossini,
  • Francesca Perticone,
  • Laura Frosio,
  • Marco Schiavo Lena,
  • Roberto Lanzi

DOI
https://doi.org/10.1530/EDM-19-0123
Journal volume & issue
Vol. 1, no. 1
pp. 1 – 5

Abstract

Read online

ACTH-secreting pheochromocytoma is a very rare cause of Cushing’s syndrome, with a high morbidity and mortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density, left adrenal mass, diagnosed as an ACTH-secreting pheochromocytoma. The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 μg s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgical control of cortisol release. Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5).